XML 26 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 21, 2025
Jun. 28, 2024
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-39269    
Entity Registrant Name Tevogen Bio Holdings Inc.    
Entity Central Index Key 0001860871    
Entity Tax Identification Number 98-1597194    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 15 Independence Boulevard    
Entity Address, Address Line Two Suite #410    
Entity Address, City or Town Warren    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07059    
City Area Code (877)    
Local Phone Number 838-6434    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 21.4
Entity Common Stock, Shares Outstanding   183,893,433  
Documents Incorporated by Reference [Text Block] Portions of the registrant’s Definitive Proxy Statement relating to the registrant’s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2024.    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 185    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Tevogen Bio Holdings Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.    
Auditor Name KPMG LLP    
Auditor Location Philadelphia, Pennsylvania    
Common Stock, $0.0001 par value per share      
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Trading Symbol TVGN    
Security Exchange Name NASDAQ    
Warrants, each exercisable for one share of Common Stock for $11.50 per share      
Title of 12(b) Security Warrants, each exercisable for one share of Common Stock for $11.50 per share    
Trading Symbol TVGNW    
Security Exchange Name NASDAQ